Expanded access to treatment

Our growth and expansion strategy helps bring medicines to new markets and adds indications, which allows more patients to access medicine. We also have a partnership strategy to serve currently underserved markets.

To increase access to medicine, we work with communities to increase patient access through the established healthcare system. We support home nursing and medicine delivery programmes, telemedicine, patient navigation tools, culturally and linguistically adapted tools as well as adherence programmes.

Pricing and reimbursement

Following regulatory approval, pricing and reimbursement are key factors in patient access that differ in each market.

We strive to set a price that reflects the benefit that the innovation delivers to patients, healthcare systems, societies, and payers – to create sustainable access to medicines for patients and continued long-term affordability to health systems to meet their patient and healthcare priorities. A means for this is generating evidence that helps quantify the clinical and patient value of a medicine. We work continuously to develop data that reflects the resolution of unmet medical needs on both an initial and an ongoing basis.

In some markets, patient access to medicine may be limited by the lack or complexity of reimbursement processes. We have several initiatives in place to support patients and treaters and bridge the gap.

Acting with a sense of urgency

Regulatory pathways for orphan drugs are implemented in several markets. Sobi’s pipeline is positioned to use these pathways to shorten the time to access for patients. A priority review will direct attention and resources to the evaluation of applications for therapies that, if approved, could provide significant improvements in the safety or efficacy of the medicine, or the diagnosis or prevention of serious conditions when compared with standard applications.

For more detailed information, please see the Annual and sustainability report.